Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

T-cell skin lymphomas are more common than B-cell skin lymphomas. Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too long. The ...

Both ultraviolet A (UVA) and ultraviolet B (UVB) light have documented efficacy for treating MF (Abe, Ohnishi, Kan, & Ishikawa, 2003; Herrmann et al., 1995; Querfeld et al., 2005) and response is ...

Innate Pharma has gained breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary ...

Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

My research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin ...